Learn how antibody to payload design is crucial for advancing ADC technology in oncology and beyond with expert insights.

Learn how radiopharmaceuticals are transforming nuclear medicine and cancer therapy through targeted diagnostics and ...

Scientists have developed a new drug, SHP1705, that targets hijacked circadian clock proteins used by glioblastoma stem cells to grow and resist treatment. Glioblastoma, the most aggressive form of ...

Cell and gene therapy is rapidly transforming the treatment of complex diseases, yet scaling production efficiently remains a challenge. Dr Tia Harmon from PHC Corporation of North America explores ...

A new study reveals how tumours hijack fat metabolism to suppress immune responses – and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant ...

Huntington’s disease remains a major challenge, but allele-selective gene editing offers new hope. By targeting only the mutant gene, this approach could provide a one-time, durable treatment. Life ...

Researchers at Moffitt Cancer Center have discovered that blocking a chemical process called nitrosylation can make aggressive NRAS-mutant melanoma more responsive to treatment. This form of skin ...

Judy Ashworth, CMO of Novadip Biosciences, shares her journey in advancing treatments for rare paediatric conditions and championing diversity in STEM. Drug Target Review sat down with Judy Ashworth, ...

Researchers at UTHealth Houston have initiated a new stem cell therapy trial aimed at reducing neuroinflammation to prevent Alzheimer’s disease before symptoms emerge, an approach that could ...

Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies. As our understanding ...

Scientists at the University of Virginia (UVA) School of Medicine have uncovered a crucial mechanism behind the lingering effects of long COVID, revealing how severe COVID-19 infections impair immune ...

Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were ...